Citius Oncology Inc (CTOR)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

Citius Oncology Inc Stock (CTOR) Company Profile

Citius Oncology Inc

Healthcare (1115)

(908) 967-6677

11 COMMERCE DRIVE, CRANFORD

최신 SEC 제출 서류

CTOR's Discussions on Twitter

CTOR을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
CTOR Citius Oncology Inc	1.05	91.58M	0	0	0	0.00
ZTS Zoetis Inc	124.65	55.21B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	16.16	51.59B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	9.83	43.51B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	31.76	37.11B	16.88B	666.71M	251.19M	0.6132
UTHR United Therapeutics Corp	464.93	20.32B	3.08B	1.24B	1.07B	25.61

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-09-23	업그레이드	Maxim Group	Hold → Buy
2024-11-27	개시	Maxim Group	Buy

Citius Oncology Inc 주식(CTOR)의 최신 뉴스

Citius Oncology Inc (CTOR) 재무 분석

Citius Oncology Inc (CTOR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

Citius Oncology Inc (CTOR)

Citius Oncology Inc Stock (CTOR) Company Profile

CTOR을(를) 다른 주식과 비교

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Citius Oncology Inc 주식(CTOR)의 최신 뉴스

Why Citius Oncology Inc. stock attracts global investorsEarnings Risk Report & Reliable Trade Execution Plans - bollywoodhelpline.com

Dow Update: Why is Citius Oncology Inc stock going downWeekly Profit Analysis & Long Hold Capital Preservation Plans - baoquankhu1.vn

Profit Review: Is Citius Oncology Inc likely to announce a buybackJuly 2025 PreEarnings & Weekly Stock Breakout Alerts - baoquankhu1.vn

Citius Oncology, Inc. (NASDAQ:CTOR): Is Breakeven Near? - simplywall.st

Can Citius Oncology Inc. stock beat market expectations this quarterJuly 2025 Setups & Long-Term Capital Growth Strategies - Улправда

Does Citius Oncology Inc. stock trade at a discount to peersPrice Action & Daily Chart Pattern Signals - Улправда

How buybacks impact Citius Oncology Inc. stock valueEarnings Growth Report & Expert Curated Trade Setups - Улправда

Aug Sectors: Why Citius Oncology Inc. stock attracts global investorsTrade Analysis Report & Weekly Watchlist of Top Performers - Улправда

Citius Oncology, Inc.Common Stock (NQ: CTOR - FinancialContent

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - GuruFocus

Citius Oncology raises $18M through direct offering - MSN

News | postregister.comCitius Oncology, Inc.Common Stock (Nasdaq:CTOR) Price Chart - FinancialContent

Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR) - marketscreener.com

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR) - PR Newswire

Citius Oncology announces pricing of $9 million public offering - MSN

What drives Citius Oncology Inc stock priceVolatility Trading Techniques & You’ve Never Seen Stock Picks Like These - earlytimes.in

Is Citius Oncology Inc a good long term investmentBear Market Strategies & Low Entry Risk Stocks - earlytimes.in

Earnings Miss: Will Citius Oncology Inc stock sustain high P E ratiosJuly 2025 Institutional & Verified Technical Signals - Bộ Nội Vụ

Citius Oncology, Inc. (NASDAQ:CTOR) Sees Significant Increase in Short Interest - Defense World

Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - 富途牛牛

Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update - MarketBeat

Citius Oncology (CTOR) Stock Analysis Report | Financials & Insights - Benzinga France

Citius Oncology’s Lymphir FDA win clouded by high upfront costs, regulatory risks, and uncertain market adoption - MSN

Citius Oncology’s LYMPHIR FDA Win Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption - TipRanks

Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why - Benzinga

Citius Oncology, Inc. Full Year Loss Increases - Nasdaq

Citius Oncology Transitions to Commercial Stage: Analyzing the 10-K Filing and the 2026 Outlook for LYMPHIR - FinancialContent

Citius Oncology (NASDAQ:CTOR) Issues Quarterly Earnings Results - MarketBeat

Citius Oncology Fiscal 2025 Loss Widens - marketscreener.com

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - WV News

Citius Pharmaceuticals, Inc. SEC 10-K Report - TradingView — Track All Markets

Citius Oncology, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 - marketscreener.com

Citius Oncology : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A) - marketscreener.com

Citius Oncology Earnings Notes - Trefis

Citius Oncology, Inc.(NasdaqCM: CTOR) added to Russell 3000E Growth Index - MarketScreener

Citius Oncology (CTOR) Price Target Increased by 100.00% to 6.12 - MSN

Citius Oncology closes $18 million in offerings to support LYMPHIR launch - Investing.com Nigeria

Citius Oncology Raises $18M Through Direct Offering - TipRanks

Citius Oncology Announces Closing of $18 Million Concurrent Regi - GuruFocus

Citius Oncology closes $18 million in offerings to support LYMPHIR launch By Investing.com - Investing.com South Africa

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Barchart.com

Citius Oncology (NASDAQ:CTOR) Shares Up 6.4%What's Next? - MarketBeat

Citius Oncology raises $18 million to support cancer therapy launch By Investing.com - Investing.com Canada

Citius Oncology, Inc. announced that it has received $16.6 million in funding - marketscreener.com

Citius Oncology (NASDAQ: CTOR) raises $1.4M, adds large warrant package - Stock Titan

Citius Oncology added to the Russell Microcap Index - MSN

Citius Oncology shares sink after announcing $18M fundraising deal - MSN

Citius Oncology raises $18 million to support cancer therapy launch - Investing.com

Citius Oncology stock tumbles after $18M capital raise By Investing.com - Investing.com Nigeria

Citius Oncology Inc (CTOR) 재무 분석

매출

순이익

현금흐름

주당 순 이익

CTOR과 유사한 종목